Argyle Capital Management Inc. bought a new position in Shire PLC (NASDAQ:SHPG) during the second quarter, Holdings Channel reports. The institutional investor bought 8,910 shares of the biopharmaceutical company’s stock, valued at approximately $1,640,000.
A number of other large investors have also modified their holdings of the company. UBS Group AG increased its stake in Shire PLC by 1,825.2% in the first quarter. UBS Group AG now owns 1,227,631 shares of the biopharmaceutical company’s stock valued at $211,030,000 after buying an additional 1,163,865 shares in the last quarter. Rockefeller Financial Services Inc. increased its stake in Shire PLC by 142.7% in the second quarter. Rockefeller Financial Services Inc. now owns 615,314 shares of the biopharmaceutical company’s stock valued at $113,266,000 after buying an additional 361,743 shares in the last quarter. Lazard Asset Management LLC increased its stake in Shire PLC by 8.3% in the first quarter. Lazard Asset Management LLC now owns 604,947 shares of the biopharmaceutical company’s stock valued at $103,989,000 after buying an additional 46,519 shares in the last quarter. BlackRock Fund Advisors increased its stake in shares of Shire PLC by 10.0% in the first quarter. BlackRock Fund Advisors now owns 591,458 shares of the biopharmaceutical company’s stock valued at $101,672,000 after buying an additional 53,889 shares during the period. Finally, Renaissance Technologies LLC increased its stake in shares of Shire PLC by 12.6% in the first quarter. Renaissance Technologies LLC now owns 313,212 shares of the biopharmaceutical company’s stock valued at $53,841,000 after buying an additional 35,100 shares during the period. Institutional investors and hedge funds own 24.26% of the company’s stock.
Shares of Shire PLC (NASDAQ:SHPG) traded down 0.57% during mid-day trading on Friday, reaching $203.05. The company had a trading volume of 973,192 shares. Shire PLC has a one year low of $147.60 and a one year high of $231.32. The stock has a market capitalization of $60.48 billion, a P/E ratio of 42.20 and a beta of 1.11. The firm has a 50 day moving average of $196.22 and a 200-day moving average of $184.13.
Shire PLC (NASDAQ:SHPG) last posted its earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $3.38 EPS for the quarter, topping the Zacks’ consensus estimate of $3.03 by $0.35. The business earned $2.43 million during the quarter, compared to analyst estimates of $2.28 billion. Shire PLC had a return on equity of 17.70% and a net margin of 13.19%. The company’s quarterly revenue was up 55.9% compared to the same quarter last year. During the same quarter last year, the company earned $2.63 EPS. Analysts forecast that Shire PLC will post $12.93 EPS for the current fiscal year.
The firm also recently announced a dividend, which will be paid on Friday, October 7th. Shareholders of record on Friday, September 9th will be issued a $0.139 dividend. The ex-dividend date of this dividend is Wednesday, September 7th. Shire PLC’s payout ratio is 15.63%.
Several equities research analysts recently issued reports on SHPG shares. Stifel Nicolaus started coverage on Shire PLC in a report on Thursday, May 26th. They set a “buy” rating and a $230.00 price target for the company. Leerink Swann reiterated an “outperform” rating and set a $225.00 price target on shares of Shire PLC in a report on Thursday, May 26th. Morgan Stanley reiterated an “overweight” rating on shares of Shire PLC in a report on Friday, June 3rd. Jefferies Group upped their price target on Shire PLC from $223.00 to $262.00 and gave the stock a “buy” rating in a report on Friday, June 3rd. Finally, Zacks Investment Research downgraded Shire PLC from a “buy” rating to a “hold” rating in a report on Wednesday, June 8th. Four equities research analysts have rated the stock with a hold rating and twenty-three have given a buy rating to the company. Shire PLC currently has an average rating of “Buy” and an average target price of $230.67.
Shire PLC Company Profile
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.
Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG).
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.